ArticleBMC microbiology2026
Genomic insights into the broad-spectrum antifungal activity of a novel Paenibacillus polymyxa strain X-11.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe Paenibacillus polymyxa group is potentially useful for regulating plant growth and controlling plant diseases. We previously isolated a novel P. polymyxa strain (X-11) that can promote plant growth. However, its antagonistic effects on plant pathogenic fungi and the underlying mechanisms therein remain unclear. To promote its utility for controlling plant diseases, strain X-11 was characterized in terms of its antagonistic effects on plant pathogenic fungi, genome sequence, genes related to antimicrobial activities, and extracellular antifungal proteins.
resultsStrain X-11 had significant antagonistic effects on several plant pathogenic fungi: Fusarium fujikuroi, Fusarium oxysporum, Magnaporthe oryzae, Botrytis cinerea, and Exserohilum turcicum. Its genome was revealed to contain 5,014 protein-coding genes as well as 49 tRNA and 10 rRNA sequences. The genome was most similar to that of P. polymyxa SC2, with 68.80% of its unique genes homologous to sequences in strain SC2. Furthermore, 85 genes related to antimicrobial activities were identified in the strain X-11 genome, including glycosyl hydrolase genes (20), serine protease genes (8), metalloproteinase genes (23), lanthionine antibiotic biosynthesis-related genes (6), and non-lanthionine antibiotic biosynthesis-related genes (2). Additionally, 14 nonribosomal peptide synthetase genes and 12 polyketide synthase genes were detected. Proteins with antifungal activities were identified in the inhibition zone between strain X-11 and Fusarium proliferatum (rice pathogen), including serine protease, lysophospholipase, metalloproteinase, glycoside hydrolase, β-glucosidase, peptidase M24, and amidase. Notably, bacillopeptidase F and bacillolysin were the most abundant antifungal proteins, suggesting that they may be the main contributors to strain X-11’s antifungal effects. An adenylation domain-containing protein involved in non-ribosomal peptide synthesis was also identified.
conclusionsThe genomic characterization of strain X-11, coupled with experimental confirmation of its broad-spectrum antifungal activity, provides a strong genetic and functional basis for its development as a promising biocontrol agent against plant fungal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.